Levetiracetam Stada

Levetiracetam, the active ingredient in Levetiracetam Stada, is an anticonvulsant presented as an oral dosage form for oral use. It is prescribed to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, offering a broad spectrum of seizure management across adult and pediatric populations.

GNH USA supplies Levetiracetam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global distribution.

Levetiracetam is an anticonvulsant that reduces neuronal excitability in various seizure types. - Partial seizures: helps achieve seizure control and lower seizure frequency. - Generalized tonic‑clonic seizures: contributes to complete seizure suppression and reduces recurrence. - Myoclonic seizures: diminishes rapid muscle jerks and improves overall seizure stability.

Levetiracetam may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Somnolence: increased sleepiness during the day. - Irritability: mood changes or agitation. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Depression: new or worsening mood disorders. - Blood disorders: rare cases of leukopenia or thrombocytopenia. - Allergic reactions: anaphylaxis or angioedema. - Multi‑organ hypersensitivity: systemic inflammatory response.

Levetiracetam requires careful consideration of patient‑specific factors before initiation. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Psychiatric history: observe for mood changes, depression, or suicidal thoughts. - Concomitant CNS depressants: avoid excessive sedation when combined with other depressants. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levetiracetam may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam plasma levels. - Phenobarbital: may reduce seizure control by decreasing drug concentration. - Strong CYP3A4 inhibitors: can increase levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Sedatives (e.g., benzodiazepines): may enhance central nervous system depression. - Hormonal contraceptives: levetiracetam may reduce contraceptive effectiveness. - Alcohol: combined use can intensify dizziness and drowsiness.